Speaker Profile
Ph.D., CEO, Insilico Medicine
Biography
Alex Zhavoronkov, PhD, is the founder and CEO of Insilico Medicine, a leading clinical-stage biotechnology company developing next-generation generative artificial intelligence and robotics platforms for drug discovery. Under his leadership, Insilico raised over $400 million in multiple rounds from expert biotechnology, healthcare, and financial investors, opened RD centers in 6 countries and regions, and partnered with multiple pharmaceutical, biotechnology, and academic institutions. Since 2021, the company nominated 21 preclinical candidates, started 6 human clinical trials, and entered Phase II with an AI-discovered novel target and AI-designed novel molecule. Since 2012, he has published over 200 peer-reviewed research papers and 3 books. He is the adjunct professor of artificial intelligence at the Buck Institute for Research on Aging.
Wellness & Aging Showcase:
Insilico Medicine
Insilico Medicine, a global clinical stage biotechnology company powered by generative AI, is connecting biology, chemistry, medicine and science research using next-generation AI systems.
Session Abstract – PMWC 2026 Silicon Valley
Track Chair: Alex Zhavoronkov, Insilico Medicine
PMWC Award Ceremony Honorees
• Steve Horvath, UCLA
• David Sinclair, Harvard
• Nir Barzilai, Albert Einstein College of Medicine
AI & Biomarkers for Measuring Aging
• Chair: Alex Zhavoronkov, Insilico Medicine
• Luigi Ferrucci, NIH
• Sara Hägg, Karolinska Institutet
• Daniel Belsky, Columbia
Epigenetic Rejuvenation & Delivery for Clinical Translation
• Ryan (Yuancheng) Lu, Whitehead Institute / MIT
• David Sinclair, Harvard
Clinical Trial Design & Functional Endpoints for Healthspan
• Nir Barzilai, Albert Einstein
Precision Aging & Longevity Focused on Limited Lifespan Evidence, Vanishing Blue Zones, and Payer ROI
• S. Jay Olshansky, University of Illinois
